Marnix Lam (1975) studied Pharmaceutical sciences (passed with distinction) and Medicine at Utrecht University. He became a resident in Nuclear Medicine, respectively Radiology and finalized his PhD thesis (2009) on radionuclide therapy in prostate cancer patients with metastatic bone pain. This was followed by a two-year postdoctoral fellowship at Stanford University School of Medicine, USA. In 2016 he was appointed Professor of Nuclear Medicine.
Translational research in molecular medicine has been the scope of his scientific work, with a focus on oncology. Bringing new radiopharmaceuticals to clinical practice. This specifically resulted in the introduction of new oncological treatment modalities in the Netherlands, such as bone seeking radiopharmaceuticals for the palliation of metastatic bone pain (Sm-153-EDTMP, Re-188-HEDP) and radioembolization for treatment of hepatic malignancies (Y-90 and Ho-166 microspheres). Current research is focussed on dosimetry of therapeutic radiopharmaceuticals, image-guided treatment technology, alfa- and beta-emitting isotopes for therapeutic purposes, intra-arterial and intra-tumor treatment approaches, and radio-immunotherapy.

Public Private Partnerships

Consultancy / (scientific) advisory board meetings and research support from Terumo / Quirem Medical B.V. No personal financial compensation, only the department of Radiology and Nuclear Medicine of the UMC Utrecht is financially compensated for these services.

Consultancy / (scientific) advisory board meetings and research support from Boston Scientific. No personal financial compensation, only the department of Radiology and Nuclear Medicine of the UMC Utrecht is financially compensated for these services.

Research support from Novartis. No personal financial compensation.

The department of Radiology and Nuclear Medicine of the UMC Utrecht receives royalties and milestone payments from Terumo / Quirem Medical B.V. No personal financial compensation.

Educational activities

Board Member of the National Education Committee on Nuclear Medicine. No personal financial compensation.

Memberships of professional societies

Member of the Dutch society of Nuclear Medicine: ‘De Nederlandse Vereniging voor Nucleaire Geneeskunde (NVNG)’. No personal financial compensation.

Member of the Royal Dutch society for promotion of the medical profession: ‘De Koninklijke Nederlandse Maatschappij ter bevordering van de Geneeskunst (KNMG)’. No personal financial compensation.

Member of ‘the European Association of Nuclear Medicine (EANM)’. No personal financial compensation.

2021 - Research grant from ‘Zorginstituut, Veelbelovende zorg’: SIRT with ¹⁶⁶Ho-microspheres in elderly and fragile patients with previously untreated unresectable liver-only metastases of colorectal cancer, CAIRO7 study of the Dutch Colorectal Cancer Group (DCCG)

2021 - Research grant from Quirem: clinical research on the safety and efficacy of holmium-166 (¹⁶⁶Ho)-microspheres radioembolization in patients with hepatic malignancies. 

2021 - Research grant from Terumo: Individualized dosimetry for holmium-166 (¹⁶⁶Ho)-radioembolization in patients with unresectable hepatocellular carcinoma; a multi-center, interventional, non-randomized, non-comparative, open label, early phase II study: iHEPAR. 

2021 - Research grant from Terumo: The RALLY study: Dose finding study for unilobar radiation lobectomy using holmium-166 (166H0)-microspheres to improve resectability in patients with HCC .

2020 - Research grant from Boston Scientific: Hepatic glass yttrium-90 (90Y)-microspheres radioembolization.

2020 - Awarded CVIR Editors’ Medal for 2020: Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. Braat, A.J.A.T., Kappadath, S.C., Ahmadzadehfar, H. et al. Cardiovasc Intervent Radiol (2019) 42(3).

2020 - Awarded Editors’ Choice Paper and top 10% downloaded papers in Medical Physics: Kunnen B et al. Feasibility of imaging 90Y microspheres at diagnositc activity levels for hepatic radioembolization treatment planning. Med Phys.

2019 - Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Efficacy of Radioembolization with 166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. J Nucl Med. 2018 Apr;59(4):582-588.

2018 - Research grant from the Dutch Cancer Society (KWF): Diagnostic accuracy of Gallium-68 PSMA PET/CT in primary staging of prostate cancer

2018 - Research grant from NWO Industrial Doctorates program: Advanced dosimetry for personalized radioembolization treatment (ADOPT)

2018 - Research grant from BTG / Boston Scientific: LUMI DEBIRI and TheraSphere for treatment of metastatic colorectal cancer (DEBIRY)

2018 - Research grant from Health Holland program: Intra-arterial lutetium-177-dotatate for treatment of patients with neuroendocrine tumor liver metastases

2017 - Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Insights into the dose-response relationship of radioembolization with resin yttrium-90 microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016 Jul;57(7):1014-9.

2016 - Research grant from the Dutch Cancer Society (KWF): Holmium-166 microspheres for radioembolization in HCC patients: new generation microspheres for individualized treatment

2016 Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres. J Nucl Med. 2015 Jun;56(6):817-23.

2016 - Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Impact of Personal Characteristics and Technical Factors on Quantification of Sodium 18F-Fluoride Uptake in Human Arteries: Prospective Evaluation of Healthy Subjects. J Nucl Med. 2015 Oct;56(10):1534-40.

2016 - Appointed as full professor of Nuclear Medicine at the University of Utrecht, The Netherlands

2014 - Research grant from Alpe d’Huzes / Dutch Cancer Society (KWF): Holmium micro-brachytherapy: an innovative intratumoral treatment modality in head and neck cancer

2014 - Appointed as honorary professor at the medical school of the People’s Liberation Army General Hospital and Military University, Beijing, China

2014 - CIRSE Award of Excellence and Innovation in Interventional Radiology

2010 - Research grant from the Dutch Cancer Society (KWF): translational research in oncology

Top 10 publications:

1. Braat AJAT, Bruijnen RCG, van Rooij R, Braat MNGJA, Wessels FJ, van Leeuwaarde RS, van Treijen MJC, de Herder WW, Hofland J, Tesselaar MET, de Jong HWAM, Lam MGEH. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020 Apr;21(4):561-570.
2. Smits ML, Nijsen JF, van den Bosch MA, Lam MGEH, Vente MA, Mali WP, van Het Schip AD, Zonnenberg BA. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012 Oct;13(10):1025-34.
3. van Kalmthout LWM, van Melick HHE, Lavalaye J, Meijer RP, Kooistra A, de Klerk JMH, Braat AJAT, Kaldeway HP, de Bruin PC, de Keizer B, Lam MGEH. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. J Urol. 2020 Mar;203(3):537-545.
4. Prince JF, van den Bosch MAAJ, Nijsen JFW, Smits MLJ, van den Hoven AF, Nikolakopoulos S, Wessels FJ, Bruijnen RCG, Braat MNGJA, Zonnenberg BA, Lam MGEH. Efficacy of Radioembolization with 166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. J Nucl Med. 2018 Apr;59(4):582-588.
5. Bastiaannet R, van Roekel C, Smits MLJ, Elias SG, van Amsterdam WAC, Doan D, Prince JF, Bruijnen RCG, de Jong HWAM, Lam MGEH. First Evidence for a Dose-Response Relationship in Patients Treated with 166Ho Radioembolization: A Prospective Study. J Nucl Med. 2020 Apr;61(4):608-612.
6. van Roekel C, Bastiaannet R, Smits MLJ, Bruijnen RC, Braat AJAT, de Jong HWAM, Elias SG, Lam MGEH. Dose-effect relationships of holmium-166 radioembolization in colorectal cancer. J Nucl Med. 2020 Jun 26.
7. Smits MLJ, Dassen MG, Prince JF, Braat AJAT, Beijst C, Bruijnen RCG, de Jong HWAM, Lam MGEH. The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):798-806.
8. Braat AJAT, Kappadath SC, Ahmadzadehfar H, Stothers CL, Frilling A, Deroose CM, Flamen P, Brown DB, Sze DY, Mahvash A, Lam MGEH. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. Cardiovasc Intervent Radiol. 2019 Mar;42(3):413-425.
9. Salem R, Padia SA, Lam MGEH, Bell J, Chiesa C, Fowers K, Hamilton B, Herman J, Kappadath SC, Leung T, Portelance L, Sze D, Garin E. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1695-1704.
10. van den Hoven A, Rosenbaum C, Elias S, de Jong H, Koopman M, Verkooijen H, Alavi A, van den Bosch M, Lam MGEH. Insights into the dose-response relationship of radioembolization with resin yttrium-90 microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016 Jul;57(7):1014-9.